全文获取类型
收费全文 | 1488篇 |
免费 | 70篇 |
国内免费 | 38篇 |
专业分类
儿科学 | 61篇 |
妇产科学 | 36篇 |
基础医学 | 124篇 |
口腔科学 | 34篇 |
临床医学 | 505篇 |
内科学 | 246篇 |
皮肤病学 | 9篇 |
神经病学 | 87篇 |
特种医学 | 141篇 |
外科学 | 48篇 |
综合类 | 26篇 |
预防医学 | 57篇 |
眼科学 | 8篇 |
药学 | 61篇 |
肿瘤学 | 153篇 |
出版年
2023年 | 8篇 |
2022年 | 4篇 |
2021年 | 12篇 |
2020年 | 11篇 |
2019年 | 11篇 |
2018年 | 21篇 |
2017年 | 9篇 |
2016年 | 16篇 |
2015年 | 38篇 |
2014年 | 41篇 |
2013年 | 60篇 |
2012年 | 35篇 |
2011年 | 43篇 |
2010年 | 39篇 |
2009年 | 50篇 |
2008年 | 47篇 |
2007年 | 49篇 |
2006年 | 45篇 |
2005年 | 42篇 |
2004年 | 51篇 |
2003年 | 39篇 |
2002年 | 50篇 |
2001年 | 50篇 |
2000年 | 35篇 |
1999年 | 56篇 |
1998年 | 96篇 |
1997年 | 93篇 |
1996年 | 85篇 |
1995年 | 66篇 |
1994年 | 52篇 |
1993年 | 57篇 |
1992年 | 22篇 |
1991年 | 30篇 |
1990年 | 30篇 |
1989年 | 27篇 |
1988年 | 39篇 |
1987年 | 14篇 |
1986年 | 17篇 |
1985年 | 19篇 |
1984年 | 14篇 |
1983年 | 7篇 |
1982年 | 9篇 |
1981年 | 7篇 |
1980年 | 8篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1977年 | 3篇 |
1976年 | 4篇 |
1922年 | 3篇 |
1905年 | 2篇 |
排序方式: 共有1596条查询结果,搜索用时 15 毫秒
41.
Linda Funk Barloon MS RN CS Psychiatric Clinical Nurse Specialist 《Journal of child and adolescent psychiatric nursing》1997,10(4):43-44
Performance Breakthroughs for Adolescents With Learning Disabilities or ADD. G. Markel & J. Greenbaum. 相似文献
42.
Characterization of the effects of cultured vascular cells on the activation of blood coagulation 总被引:9,自引:0,他引:9
The coagulant properties of intact bovine vascular cells (aortic endothelial and smooth muscle cells) and human vascular cells (cutaneous and foreskin microvascular cells, umbilical venous endothelium) grown in vitro were studied. Compared to nonvascular cells (fibroblasts, corneal endothelial cells, fetal lung or intestinal mucosal cells), vascular cells had little procoagulant activity. Radioimmunologic measurement of thrombin in recalcified plasma demonstrated markedly lower concentrations of thrombin in the presence of vascular endothelial and smooth muscle cells compared to corneal endothelial and fetal lung cells. The low thrombin concentrations were not a consequence of thrombin binding to the vascular cells nor were they due to accelerated thrombin inactivation by antithrombin-III or alpha 2-macroglobulin. Neither vascular cells nor the nonvascular cells promoted contact activation of plasma as measured by a sensitive specific assay for kallikrein. Studies with intact cell monolayers and purified factors VIIa and X indicated that while nonvascular cells express tissue factor activity, vascular cells do not exhibit this property. These data suggest that the nonthrombogenic nature of intact vascular cells is due to their failure to initiate contact activation and to express tissue factor activity. In addition, the primary difference in coagulant potential between vascular cells and nonvascular cells is the lack of tissue factor expression by the vascular cells. 相似文献
43.
Tinhofer Inge; Marschitz Ingrid; Kos Marion; Henn Traudl; Egle Alexander; Villunger Andreas; Greil Richard 《Blood》1998,91(11):4273-4281
44.
45.
August CS; King E; Githens JH; McIntosh K; Humbert JR; Greensheer A; Johnson RB 《Blood》1976,48(4):491-498
Marrow transplantation was attempted in a 13-yr-old boy with congenital hypoplastic anemia who had never responded to corticosteroid therapy. Prior to the transplant, he had received 238 transfusions, at least 12 of which were from his father. He was prepared for grafting with antilymphocyte globulin, procarbazine, and total body irradiation (1000 rads). The patient, whose red cells were Group B, then received marrow cells from his Group O, histocompatible, sister. Thereafter, reticulocytes, Group O erythrocytes, and female leukocytes appeared in the peripheral blood. Erythroid precursors were seen in the patient's marrow for the first time in his life, and all lacked fluorescent Y chromosomes. Dividing cells were all female. After initially progressing well, the patient developed interstitial pneumonia and died 55 days after the transplant. The successful erythroid graft suggested that this patient's failure to produce red blood cells was due to a defective stem cell rather than to a humoral defect, plasma inhibitor, or abnormal marrow microenvironment. It suggested further that sibling marrow may be engrafted in patients who have received multiple transfusions, even from a parent. 相似文献
46.
OBJECTIVE: To study the predictive factors for avascular necrosis (AVN) of
bone in patients with systemic lupus erythematosus (SLE). METHOD: The
records of 38 SLE patients who developed clinically apparent AVN during the
course of their disease were reviewed. Information on clinical
presentation, corticosteroid usage and autoantibody profiles was obtained,
and comparison was made between these patients and 143 consecutive control
SLE patients who did not have AVN. RESULTS: The point prevalence of AVN in
our SLE population was 12%. Patients with AVN, when compared with controls,
had a significantly higher incidence of neurological disease (39% vs 14%; P
< 0.001) and Cushingoid body habitus after steroid treatment (79% vs
53%; P = 0.004). The highest cumulative prednisolone dose in 1 and 4 months
was significantly higher in the AVN group than the controls (1.8 vs 1.1 and
4.5 vs 2.8 g, respectively; P < 0.01 in both) and showed a linear trend
with the incidence of AVN (chi2 test for trend, P < 0.01 in both). Lupus
anticoagulant was associated with AVN (P = 0.02, odds ratio 2.88 [1.14-
7.28]). Logistic regression analysis revealed that the highest cumulative
prednisolone dose administered in 4 months, the maximum and mean daily
prednisolone dosage, and the lupus anticoagulant were independent risk
factors for AVN. CONCLUSIONS: Corticosteroid remains the major predisposing
factor for AVN in SLE. Patients who require an initial high-dose steroid
for disease control are at risk of AVN, especially if they are positive for
the lupus anticoagulant or develop Cushingoid habitus after steroid
treatment. High-risk patients should be closely monitored so that early AVN
can be diagnosed by sensitive techniques such as magnetic resonance imaging
and radioisotope bone scanning.
相似文献
47.
delta-Aminolevulinate dehydratase in human erythroleukemia cells: an immunologically distinct enzyme 总被引:4,自引:0,他引:4
Physicochemical and immunologic properties of delta-aminolevulinate (ALA) dehydratase in human K562 erythroleukemia cells were examined. ALA dehydratase activity was found to increase in K562 cells after treatment with butyric acid or selenium oxide. Enzyme activity in untreated K562 cells was comparable to that in normal adult erythrocytes but was increased three- to six-fold in K562 cells treated with 1.2 mmol/L butyric acid or 0.03 mmol/L selenium oxide. The Michaelis-Menten constant (Km), the inhibitor constant (Ki), and elution profile by diethylaminoethyl (DEAE) cellulose chromatography were similar for ALA dehydratase from K562 cells and normal human adult and human fetal erythrocytes. However, ALA dehydratase from K562 cells did not react with a monospecific rabbit antibody against ALA dehydratase purified from normal adult erythrocytes, although the antibody reacted with the enzyme from normal adult and fetal red cells. These findings indicate that ALA dehydratase in K562 cells is immunologically distinct from the normal enzyme. 相似文献
48.
Lisa Pleyer Sonja Burgstaller Michael Girschikofsky Werner Linkesch Reinhard Stauder Michael Pfeilstocker Martin Schreder Christoph Tinchon Thamer Sliwa Alois Lang Wolfgang R. Sperr Peter Krippl Dietmar Geissler Daniela Voskova Konstantin Schlick Josef Thaler Sigrid Machherndl-Spandl Georg Theiler Otto Eckmüllner Richard Greil 《Annals of hematology》2014,93(11):1825-1838
Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, and the drug can only be used off-label in these patients. We previously reported on the efficacy and safety of azacitidine in 155 AML patients treated within the Austrian Azacitidine Registry (clinicaltrials.gov identifier NCT01595295). We herein update this report with a population almost twice as large (n?=?302). This cohort included 172 patients with >30 % BM blasts; 93 % would have been excluded from the pivotal AZA-001 trial (which led to European Medicines Agency (EMA) approval of azacitidine for high-risk myelodysplastic syndromes (MDS) and AML with 20–30 % BM blasts). Despite this much more unfavorable profile, results are encouraging: overall response rate was 48 % in the total cohort and 72 % in patients evaluable according to MDS-IWG-2006 response criteria, respectively. Median OS was 9.6 (95 % CI 8.53–10.7)?months. A clinically relevant OS benefit was observed with any form of disease stabilization (marrow stable disease (8.1 months), hematologic improvement (HI) (9.7 months), or the combination thereof (18.9 months)), as compared to patients without response and/or without disease stabilization (3.2 months). Age, white blood cell count, and BM blast count at start of therapy did not influence OS. The baseline factors LDH >225 U/l, ECOG ≥2, comorbidities ≥3, monosomal karyotype, and prior disease-modifying drugs, as well as the response-related factors hematologic improvement and further deepening of response after first response, were significant independent predictors of OS in multivariate analysis. Azacitidine seems effective in WHO-AML, including patients with >30 % BM blasts (currently off-label use). Although currently not regarded as standard form of response assessment in AML, disease stabilization and/or HI should be considered sufficient response to continue treatment with azacitidine. 相似文献
49.
50.